ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The efficacy of drugs in patients with chronic myeloid leukemia (CML) has also been measured through FRET-based biosensor-mediated monitoring of the activity of BCR-ABL kinase that is causatively expressed in CML patients20.